GlassScriptPhysician profile
Brian K Haag
NPI 1932213402
$3,323.46
in general payments reported to CMS, 2019-2025
32 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,320 · 2022: $780 · 2023: $514 · 2024: $506 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $534.90 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.89 | 2021-2024 | Jardiance |
| Abbvie INC. | $315.54 | 2021-2024 | |
| Lilly USA, LLC | $198.91 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $160.76 | 2021-2024 | Freestyle Libre |
| Amgen INC. | $160.11 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $149.46 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $143.91 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $111.86 | 2021-2025 | Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $111.70 | 2021-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $105.07 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $95.34 | 2021-2022 | |
| Astellas Pharma US INC | $83.01 | 2021-2025 | Veozah |
| Eisai INC. | $79.77 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $63.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.62 | 2021-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $51.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.49 | 2021-2022 | |
| Exact Sciences Corporation | $49.65 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $47.26 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $42.52 | 2023-2024 | Quviviq |
| Dexcom, INC. | $33.01 | 2022-2023 | Dexcom G6 Transmitter |
| Aytu Biopharma, INC. | $30.46 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.98 | 2021 | |
| Biogen, INC. | $18.71 | 2021 | |
| Lifescan, INC. | $16.04 | 2023 | |
| Halozyme INC | $15.45 | 2023 | |
| Genentech USA, INC. | $14.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2021 | |
| Boston Scientific Corporation | $14.39 | 2024 | Varithena Administration Pack |
| Nabriva Therapeutics, Plc | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Haag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.